July 21 (Reuters) - CSL Behring :
* CSL Behring receives orphan-drug exclusivity for Haegarda (C1 esterase inhibitor subcutaneous human )
* CSL Behring - U.S. FDA has granted company seven years of orphan-drug exclusivity for Haegarda
July 21 (Reuters) - CSL Behring :
* CSL Behring receives orphan-drug exclusivity for Haegarda (C1 esterase inhibitor subcutaneous human )
* CSL Behring - U.S. FDA has granted company seven years of orphan-drug exclusivity for Haegarda